Hyperlipoproteinemia: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
Line 86: | Line 86: | ||
|Autosomal Recessive | |Autosomal Recessive | ||
|Normal or '''↑''' | |Normal or '''↑''' | ||
| | |'''↓''' | ||
| | |'''↓''' '''↓''' '''↓''' | ||
|'''↑↑↑↑''' | |'''↑↑↑↑''' | ||
|Milky | |Milky | ||
| | |'''↑↑↑↑''' | ||
| | |'''↓''' | ||
|LPL gene mutation | | -LPL gene mutation | ||
| | | -Fat tolerance markedly abnormal | ||
-Carbohydrate inducibility may be abnormal | |||
|Treatment for hyperlipoproteinemia type 1 is intended to control blood triglyceride levels with a very low-fat diet | |Treatment for hyperlipoproteinemia type 1 is intended to control blood triglyceride levels with a very low-fat diet | ||
|<nowiki>-Recurrent Pancreatitis</nowiki> | |<nowiki>-Recurrent Pancreatitis</nowiki> |
Revision as of 22:07, 8 November 2016
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Classification
Hyperlipoproteinemia | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Type I: Familial hyperchylomicronemia | Type II | Type III: Dysbetalipoproteinemia | Type IV: Primary hypertriglyceridemia | Type V: Mixed hyperlipoproteinemia | |||||||||||||||||||||||||||||||||||||||||||||||||||
Type A: Familial hypercholesterolemia | Type B: Familial combined hyperlipidemia | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Synopsis
Hyperlipoproteinemia | Synonyms | Problems | Labs description | Treatment |
---|---|---|---|---|
Type I | Buerger-Gruetz syndrome, primary hyperlipoproteinaemia, or familial hyperchylomicronemia | Decreased lipoprotein lipase (LPL) or altered ApoC2 | Elevated chylomicrons | Diet control |
Type IIa | Polygenic hypercholesterolaemia or familial hypercholesterolemia | LDL receptor deficiency | Elevated LDL only | Bile acid sequestrants, statins, niacin |
Type IIb | Combined hyperlipidemia | Decreased LDL receptor and increased ApoB | Elevated LDL, VLDL and triglycerides | Statins, niacin, gemfibrozil |
Type III | Familial Dysbetalipoproteinemia | Defect in ApoE synthesis | Increased IDL | Drug of choice: Gemfibrozil |
Type IV | Endogenous Hyperlipemia | Increased VLDL production and decreased elimination | Increased VLDL | Drug of choice: Niacin |
Type V | Familial Hypertriglyceridemia | Increased VLDL production and decreased LPL | Increased VLDL and chylomicrons | Niacin, gemfibrozil |
Differential Diagnosis
Diseases | Mode of Inheritance | Laboratory Findings | Other Findings | Management | Complications | Prognosis | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Lipid Profile | Other Laboratory Findings | |||||||||||||
Total Cholesterol | LDL | HDL | Triglycerides | Plasma Appearance | Chylomicrons | VLDL | Genetic mutations | |||||||
Primary Hyperlipoprotenemia | Type I | Autosomal Recessive | Normal or ↑ | ↓ | ↓ ↓ ↓ | ↑↑↑↑ | Milky | ↑↑↑↑ | ↓ | -LPL gene mutation | -Fat tolerance markedly abnormal
-Carbohydrate inducibility may be abnormal |
Treatment for hyperlipoproteinemia type 1 is intended to control blood triglyceride levels with a very low-fat diet | -Recurrent Pancreatitis
-Rarely life threatening |
Good |
Type IIA | ||||||||||||||
Type IIB | ||||||||||||||
Type III | ||||||||||||||
Type IV | Autosomal Recessive
& Autosomal Dominant |
Normal or ↑ | Prebeta-HDL ↑
& HDL-C |
↑↑ | Clear or Cloudy | Normal | ↑ | -LPL genes (Gly188Glu,Asp9Asn, Asn291Ser,Ser447Ter)
-APOA5 -LMF1 -GPIHBP1 |
Hyperglycemia, Pancytopneia and pseudo-Niemann
pick cells |
-Weight reduction
-Fibrates -Gene therapy |
-Ischemic Heart Disea
-Recurrent Pancreatitis -NIDDM -NAFLD |
|||
Type V | ||||||||||||||
Secondary Hyperlipoprotenemia | Diabetes Mellitus | |||||||||||||
Alcohol Abuse | ||||||||||||||
Estrogen Therapy | ||||||||||||||
Glucocorticoid therapy | ||||||||||||||
Renal Disease | ||||||||||||||
Obesity | ||||||||||||||
High-fat diet | ||||||||||||||
Poor physical activity | ||||||||||||||
Paraproteinemic disorders | ||||||||||||||
Hypothyroidism |